ClinPGx Blog (Page 39)

Sign in Subscribe

More issues

Mixed Results for Genotype-guided Warfarin Dosing

Update (12/17/2013):New perspective piece from the New England Journal of Medicine The December 12 issue of the New England Journal of Medicine includes a perspective piece discussing the recent trial results on coumarin dosing. This article, Pharmacogenetics and Coumarin Dosing — Recalibrating Expectations, by Zineh et al from

Controversy over the PGx of Cisplatin-Induced Hearing Loss in children

Hearing loss is a common side effect in cancer patients treated with cisplatin, with significant effects on quality of life. Age, dosage, cranial irradiation and concomitant vincristine use are all established risk factors for cisplatin ototoxicity. However, there is debate surrounding genetic variants associated with risk and the clinical utility

PharmGKB Drug Labels: Description, Update and New Features

PharmGKB has recently added new information to drug label entries, standardized the annotations, and updated the website display. The overview page for drug labels contains high level information about each label at a glance, including: * Whether the drug label is currently on the FDA's Table of Pharmacogenomic Biomarkers

PG&G publication: Mycophenolic acid Pathway

Mycophenolic acid (MPA) is an immunosuppressive agent used to prevent rejection in organ transplantation. We recently have published this pathway summary in the Pharmacogenetics and Genomics Journal.The article and included figure describe the metabolism of MPA and its prodrug mycophenolate mofetil. MPA is a noncompetitive, selective and reversible inhibitor

FDA-Approved Drug Labels, Pharmacogenomics and PharmGKB Evaluation

FDA-approved drug label standardization and pharmacogenomics People often use the wording "FDA drug labels" instead of "FDA-approved drug labels." To be clear, the FDA does not write drug labels; it is the responsibility of the drug company to provide them. The FDA reviews and

Viva La Evidence

We came across this brilliant music video “Viva La Evidence” by Dr. James McCormack. It’s a parody of Coldplay's Viva La Vida and the lyrics cover many important topics of evidence based medicine, its history, principles and aims. What a fun way to explain the hierarchy of

Venlafaxine Pathway published in PG&G

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed for the treatment of depression disorders. We recently have published the Venlafaxine Pathway summary in the Pharmacogenetics and Genomics Journal.The article describes the metabolism of venlafaxine, with cytochrome P450 2D6 (CYP2D6) being the major enzyme involved in the formation of

NIH funds ClinGen: a resource to establish which genetic variants are clinically relevant

The NIH (NHGRI and NICHD) has awarded more than $25 million over the course of 4 years for the development of the Clinical Genome Resource (ClinGen). The aim of ClinGen is to provide a framework for the evaluation of genetic variants that are clinically relevant, working with the NCBI which

The Curation Economy

In an October 7th article in The Huffington Post blog section, Steve Rosenbaum discusses the development of a so-called "Curation Economy". Rosenbaum writes that the creation of content on the web is increasing at an exponential rate, leading to a massive amount of raw and unfiltered data.

CPIC publishes guidelines for IFNL3 (IL28B) and peginterferon alpha based regimens

Guidelines regarding the use of IFNL3 (formerly known as IL28B) genotypes in peginterferon alpha based therapies have been accepted for publication in the Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Hepatitis C virus (HCV) infection affects more than 150 million people worldwide and is one of